The Use of Candida auris Therapies based on Nanotechnology as Potential Novel Strategy against COVID-19 Infection

Billamboz M, Fatima Z, Hameed S, Jawhara S. Promising drug candidates and new strategies for fighting against the emerging superbug Candida auris. Microorganisms 2021; 9(3): 634.

Calvo B, Melo ASA, Perozo-Mena A, et al. First report of Candida auris in America: Clinical and microbiological aspects of 18 episodes of Candidemia. J Infect 2016; 73: 369-374.

Villanueva-Lozano, H., Treviño-Rangel, R. de J., González, G.M., et al. Outbreak of Candida auris infection in a COVID-19 hospital in Mexico. Clin Microbiol Infect 2021; 27: 813-816.

Almeida Jr. JN, Francisco EC, Hagen F, et al. Emergence of Candida auris in Brazil in a COVID-19 intensive care unit. J Fungi 2021; 7: 220.

PAHO-2021. Pan American Health Organization/World Health Organization (PAHO/WHO). Candida auris outbreaks in health care services in the context of themCIVID-19 pandemia. April 6, 2021. https://www.paho.org/en/documents/epidemiological-alert-candida-auris-outbreaks-health-care-services-context-covid-19.

Rossato L. COVID-19 and Candida auris co-infection: an increasing threat. J Trop Pathol 2021; 50: 73-75.

Prestel C, Anderson E, Forsberg K, et al. Candida auris outbreak in a COVID-19 specialty care unit, Florida, July–August 2020, Morbidity mortality weekly report (US Department of Health and Human Services/Centers for Disease Control and Prevention) (MMWR) 2021; 70: 56-57

Rossato L, Colombo AL. Candida auris: What have we learned about its mechanisms of pathogenicity? Front Microbiol 2018; 9: 3081.

Larwood DJ. Nikkomycin Z-Ready to Meet the Promise? J Fungi (Basel) 2020;6 (4):261.

Bentz ML, Nunnally N, Lockhart SR, et al. Antifungal activity of nikkomycin Z against Candida auris. J Antimicrob Chemother. 2021; 76(6):1495-1497.

Chybowska AD, Childers DS, Farrer RA. Nine things genomics can tell us about Candida auris. Front Genet 2020; 11: 351.

Ahmad S, Alfouzan W. Candida auris: Epidemiology, diagnosis, pathogenesis, antifungal susceptibility, and infection control measures to combat the spread of infections in healthcare facilities. Microorganisms 2021; 9: 807.

Bidaud AL, Chowdhary A, Dannaoui E. Candida auris: An emerging drug resistant yeast – a mini-review. J Mycol Med 2018; 28: 568–573.

Bhattacharya, S., Holowka, T., Orner, et al. Gene duplication associated with increased Fluconazole tolerance in Candida auris cells of advanced generational age. Sci. Rep. 2019; 9: 5052.

Kim SH, Iyer KR., Pardeshi L, et al. Genetic analysis of Candida auris implicates Hsp90 in morphogenesis and azole tolerance and Cdr1 in azole resistance. mBio 2019; 10: e02529-18.

Kean R, Delaney C, Sherry L, et al. Transcriptome assembly and profiling of Candida auris reveals novel insights into biofilm-mediated resistance. mSphere 2018; 3: e00334-18.

Kean R, Ramage G. Combined antifungal resistance and biofilm tolerance: the global threat of Candida auris. mSphere 2019; 4: e00458-19.

Muñoz JF, Gade L, Chow NA, et al. Genomic insights into multidrug-resistance, mating and virulence in Candida auris and related emerging species. Nat Commun 2018; 9: 5346.

Muñoz JF, Welsh RM, Shea T, et al. Chromosomal rearrangements and loss of subtelomeric adhesins linked to clade-specific phenotypes in Candida auris. bioRxiv [Preprint]. 2019; doi: 10.1101/754143.

Seiler GT, Ostrosky-Zeichner L. Investigational agents for the treatment of resistant yeasts and molds. Curr Fungal Infect Rep 2021; https://doi.org/10.1007/s12281-021-00419-5.

Hager CL, Larkin EL, Long L, et al. In vitro and in vivo evaluation of the antifungal activity of APX001A/APX001 against Candida auris. Antimicrob Agents Chemother 2018; 62: e02319-17.

Berkow EL, Lockhart SR. Fluconazole resistance in Candida species: a current perspective. Infect. Drug Resist 2017; 10: 237-245.

Larkin EL, Long L, Isham N, et al. A novel 1,3-beta-d-glucan inhibitor, Ibrexafungerp (Formerly SCY-078), shows potent activity in the lower pH environment of vulvovaginitis. Antimicrob Agents Chemother 2019; 63: e02611-18.

Wiederhold NP, Lockhart SR, Najvar LK, et al. The fungal Cyp51-specific inhibitor VT-1598 demonstrates in vitro and in vivo activity against Candida auris. Antimicrob Agents Chemother 2019; 63: e02233-18.

Brand SR, Degenhardt TP, Person K, et al. A phase 2, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of orally administered VT-1161 in the treatment of recurrent vulvovaginal candidiasis. Am J Obstet Gynecol 2018; 218: 624.e1–624.e9.

Lepak AJ, Zhao M, Andes DR. Pharmacodynamic evaluation of Rezafungin (CD101) against Candida auris in the neutropenic mouse invasive candidiasis model. Antimicrob Agents Chemother 2018; 62:e01572-18.

Angulo D. Open-Label Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) in Patients With Candidiasis Caused by Candida Auris (CARES). https://clinicaltrials.gov/ct2/show/NCT03363841.

Nishikawa H, Fukuda Y, Mitsuyama J. et al. In vitro and in vivo antifungal activities of T-2307, a novel arylamidine, against Cryptococcus gattii: An emerging fungal pathogen. J Antimicrob Chemother 2017; 72: 1709-1713.

Murray A, Cass L, Ito K, et al. PC945, a novel inhaled antifungal agent, for the treatment of respiratory fungal infections. J Fungi 2020; 6: 373.

Singh R, Kaur M, Chakrabarti A et al. Biofilm formation by Candida auris isolated from colonising sites and candidemia cases. Mycoses 2019; 62: 706-709.

Leach MD, Farrer RA, Tan K, et al. Hsf1 and Hsp90 orchestrate temperature-dependent global transcriptional remodelling and chromatin architecture in Candida albicans. Nat Commun 2016; 7:11704.

Chakrabarti A, Sood P. On the emergence, spread and resistance of Candida auris: Host, pathogen and environmental tipping points. J Med Microbiol 2021; 70: 001318.

OMS, 2020. Antimicrobial resistance. https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance. (Accessed on July 2, 2021)

Misra SK, Pathak K. Supercritical fluid technology for solubilization of poorly water-soluble drugs via micro- and nanosized particle generation. ADMET and DMPK, 2020; 8: 355-374.

Emig D, Ivliev A, Pustovalova O, et al. Drug target prediction and repositioning using an integrated network-based approach. PLoS One. 2013; 8: e60618.

Aghaei Gharehbolagh S, Izadi A, Talebi M, et al. New weapons to fight a new enemy: A systematic review of drug combinations against the drug-resistant fungus Candida auris. Mycoses. 2021, In press. doi: 10.1111/myc.13277.

Shamshina JL, Barber PS, Rogers RD. Ionic liquids in drug delivery. Expert Opin Drug Deliv 2013; 10: 1367-1381.

Vandana KR, Prasanna Raju Y, Harini Chowdary V, et al. An overview on in situ micronization technique - An emerging novel concept in advanced drug delivery. Saudi Pharm J 2014; 22: 283-289.

Xue H, Li J, Xie H, Wang Y. Review of drug repositioning approaches and resources. Int J Biol Sci 2018; 14: 1232-1244.

Ahmad A, Wei Y, Syed F, et al. Amphotericin B-conjugated biogenic silver nanoparticles as an innovative strategy for fungal infections. Microb Pathogen 2016; 99: 271–281.

Amaral AC, Saavedra PHV, Oliveira Souza AC, et al., Miconazole loaded chitosan-based nanoparticles for local treatment of vulvovaginal candidiasis fungal infections. Colloids Surf B Biointerfaces. 2019; 174: 409-415.

Araújo J, Martín-Pastor M, Pérez L, et al. Development of anacardic acid-loaded zein nanoparticles: Physical chemical characterization, stability, and antimicrobial improvement. J Mol Liq 2021; 332: 115808.

Albertini B, Passerini N, Di Sabatino M, et al. Polymer-lipid based mucoadhesive microspheres prepared by spray-congealing for the vaginal delivery of econazole nitrate, Eur J Pharm Sci 2009; 36(4-5): 591–601.

Monteiro DR, Gorup LF, Silva S, et al. Silver colloidal nanoparticles: antifungal effect against adhered cells and biofilms of Candida albicans and Candida glabrata. Biofouling. 2011; 27(7):711-9.

Lara HH, Ixtepan-Turrent L, Yacaman MJ, et al. Inhibition of Candida auris biofilm formation on medical and environmental surfaces by silver nanoparticles. ACS Appl Mater Interf 2020; 12: 19.

Vazquez-Muñoz R, Lopez FD, Lopez-Ribot JL. Silver Nanoantibiotics display strong antifungal activity against the emergent multidrug-resistant yeast Candida auris under both planktonic and biofilm growing conditions. Front Microbiol 2020a; 11:1673.

Gangadoo S, Elbourne A, Medvedev AE. et al. Facile route of fabricating long-term microbicidal silver nanoparticle clusters against Shiga toxin-producing Escherichia coli O157:H7 and Candida auris. Coatings 2020; 10: 28.

Vazquez-Muñoz R, Lopez FD, Lopez-Ribot JL. Bismuth nanoantibiotics display anticandidal activity and disrupt the biofilm and cell morphology of the emergent pathogenic yeast Candida auris. Antibiotics 2020b; 9: 461.

Bonilla JJA, Honorato L, de Oliveira DFC, et al. Silver chitosan nanocomposites as a potential treatment for superficial candidiasis. Med Mycol 2021; myab028. https://doi.org/10.1093/mmy/myab028

Gupta A, Briffa SM, Swingler S, et al. Synthesis of silver nanoparticles using curcumin-cyclodextrins loaded into bacterial cellulose based hydrogels for wound dressing applications. Biomacromolecules 2020; 21:1802-1811.

Sherin P, Kuriakose S. Synthesis of Superparamagnetic iron oxide nanoparticles stabilized by biocompatible supramolecular ?-cyclodextrin for biomedical applications. Mater Today Proc 2019; 11:1030-1035.

Kamli MR, Srivastava V, Hajrah NH, et al. Phytogenic fabrication of Ag-Fe bimetallic nanoparticles for cell cycle arrest and apoptosis signaling pathways in Candida auris by generating oxidative stress. Antioxidants (Basel, Switzerland) 2021a; 10(2): 182.

Kamli MR, Srivastava V, Hajrah NH, et al. Facile bio-fabrication of Ag-Cu-Co trimetallic nanoparticles and its fungicidal activity against Candida auris. J Fungi 2021b; 7: 62.

Cleare LG, Li KL, Abuzeid WM, et al. NO Candida auris: Nitric oxide in nanotherapeutics to combat emerging fungal pathogen Candida auris. J Fungi 2020; 6: 85.

Barreto TL, Rossato L, de Freitas ALD, et al. Miltefosine as an alternative strategy in the treatment of the emerging fungus Candida auris. Inter J Antimicrob Agents 2020; 56: 106049.

Spadari CC, de Bastiani FWMDS, Lopes LB, Ishida K. Alginate nanoparticles as non-toxic delivery system for miltefosine in the treatment of candidiasis and cryptococcosis. Int J Nanomedicine 2019; 14: 5187-5199.

Hamdy R, Fayed B, Hamoda AM, et al. Essential oil-based design and development of novel anti-candida azoles formulation. Molecules 2020; 25, 1463.

Zhang L, Li X, Zhu S, et al. Dermal targeting delivery of terbinafine hydrochloride using novel multi-ethosomes: A new approach to fungal infection treatment. Coatings 2020; 10: 304.

Silva C de B, Guterres SS, Weisheimer V, Schapoval EE. Antifungal activity of the lemongrass oil and citral against Candida spp. Braz J Infect Dis 2008; 12(1):63-66.

Ahmad A, Khan A, Akhtar F, et al. Fungicidal activity of thymol and carvacrol by disrupting ergosterol biosynthesis and membrane integrity against Candida. Eur J Clin Microbiol Infect Dis. 2011; 30(1): 41-50.

Shreaz S, Wani WA, Behbehani JM, et al. Cinnamaldehyde and its derivatives, a novel class of antifungal agents. Fitoterapia. 2016; 112:116-131.

Miranda-Cadena K, Dias M, Costa-Barbosa A, et al. Development and characterization of monoolein-based liposomes of carvacrol, cinnamaldehyde, citral, or thymol with Anti-Candida Activities. Antimicrob Agents Chemother 2021; 65(4):e01628-1620.

Hornby JM, Jensen EC, Lisec AD, et al. Quorum sensing in the dimorphic fungus Candida albicans is mediated by farnesol. Appl Environ Microbiol 2001; 67(7): 2982-2992.

Langford ML, Atkin AL, Nickerson KW. Cellular interactions of farnesol, a quorum-sensing molecule produced by Candida albicans. Future Microbiol 2009; 4: 1353-1362.

Nagy F, Vitális E, Jakab Á, et al. In vitro and in vivo effect of exogenous farnesol exposure against Candida auris. Front Microbiol. 2020a;11: 957.

Nagy F, Tóth Z, Daróczi L, et al. Farnesol increases the activity of echinocandins against Candida auris biofilms. Med Mycol. 2020b; 58(3): 404-407.

Srivastava V, Ahmad A. Abrogation of pathogenic attributes in drug resistant Candida auris strains by farnesol. PLoS One 2020; 15(5): e0233102.

Bezerra CF, de Alencar Júnior JG, de Lima Honorato R, et al. Antifungal activity of farnesol incorporated in liposomes and associated with fluconazole. Chem Phys Lipids 2020; 233:104987.

Cavassin FB, Baú-Carneiro JL, Vilas-Boas RR., et al. Sixty years of Amphotericin B: An overview of the main antifungal agent used to treat invasive fungal infections. Infect dis ther 2021; 10: 115–147.

Wang X, Mohammad IS, Fan L, et al. Delivery strategies of amphotericin B for invasive fungal infections, Acta Pharm Sin B 2021; In press. https://doi.org/10.1016/j.apsb.2021.04.010

Hamill, RJ. Amphotericin B formulations: a comparative review of efficacy and toxicity. Drugs 2013; 73(9): 919–934.

Herrada J, Gamal A, Long L, et al. In vitro and in vivo antifungal activity of AmBisome compared to conventional amphotericin B and fluconazole against Candida auris. Antimicrob Agents Chemother 2021; 65(6):e00306-21.

Rodriguez YJ, Quejada LF, Villamil JC, et al. Development of amphotericin B micellar formulations based on copolymers of poly (ethylene glycol) and poly(?-caprolactone) conjugated with retinol. Pharmaceutics 2020; 12: 196.

Chatzimoschou A, Giampani A, Meis JF, et al. Activities of nine antifungal agents against Candida auris biofilms. Mycoses 2020; 64: 381-384.

Griffith N, Larry Danziger L. Candida auris urinary tract infections and possible treatment. Antibiotics 2020; 9: 898.

Alves D, Vaz AT, Grainha T, et al. Design of an antifungal surface embedding liposomal amphotericin b through a mussel adhesive-inspired coating strategy. Front Chem 2019; 7: 431.

Gudz KY, Antipina LY, Permyakova ES, et al., Ag-doped and antibiotic-loaded hexagonal boron nitride nanoparticles as promising carriers to fight different pathogens. ACS Appl Mater Interfaces 2021; 13(20): 23452-23468.

Tutaj K, Szlazak R, Szalapata K, et al. Amphotericin B-silver hybrid nanoparticles: synthesis, properties and antifungal activity. Nanomed-nanotechnol 2016; 12: 1095–1103.

Jafari M, Abolmaali SS, Tamaddon AM, et al. Nanotechnology approaches for delivery and targeting of Amphotericin B in fungal and parasitic diseases. Nanomedicine (London, England) 2021; 16: 857–877.

Gudz KY, Permyakova ES, Matveev AT, et al. Pristine and antibiotic-loaded nanosheets/nanoneedles-based boron nitride films as a promising platform to suppress bacterial and fungal Infections. ACS Appl Mater Interfaces 2020; 12(38):42485-42498.

Dennis EK, Kim JH, Parkin S, et al. Distorted Gold(I)-Phosphine Complexes as Antifungal Agents. J Med Chem 2020; 63(5): 2455-2469.

Domingues Bianchin M, Borowicz SM, da Rosa Monte Machado G, et al. Lipid core nanoparticles as a broad strategy to reverse fluconazole resistance in multiple Candida species. Colloids Surf B Biointerfaces. 2019; 175:523-529.

Sadeghi Ghadi Z, Dinarvand R, Asemi N, et al. Preparation, characterization and in vivo evaluation of novel hyaluronan containing niosomes tailored by Box-Behnken design to co-encapsulate curcumin and quercetin. Eur J Pharm Sci 2019; 130: 234-246.

Sadeghi-Ghadi Z, Vaezi A, Ahangarkani F, et al. Potent in vitro activity of curcumin and quercetin co-encapsulated in nanovesicles without hyaluronan against Aspergillus and Candida isolates. J Mycol Med 2020; 30(4): 101014.

Hashemi MM, Rovig J, Holden BS, et al. Ceragenins are active against drug-resistant Candida auris clinical isolates in planktonic and biofilm forms. J Antimicrob Chemother 2018; 73(6):1537-1545.

Eldesouky HE, Lanman NA, Hazbun TR, et al. Aprepitant, an antiemetic agent, interferes with metal ion homeostasis of Candida auris and displays potent synergistic interactions with azole drugs. Virulence 2020; 11(1): 1466-1481.

Kim HR, Eom YB. Antifungal and anti-biofilm effects of 6-shogaol against Candida auris. J Appl Microbiol. 2021; 130(4): 1142-1153.